The article reports on the results of an international randomized trial among men who have sex with men or who identify as transgender or female that suggest that preexposure prophylaxis (PrEP) treatment for HIV does not lead to risky sexual behavior. The study found that placebo recipients who...
In other cases, prophylactic treatment can be provided after a patient has been exposed to an infectious agent but before any symptoms have appeared, in an effort to allow that patient'simmune systema better chance to ward off infection. Post-exposure prophylaxis is most often used when dealing ...
摘要: Reports a case of a health-care worker acquiring HIV infection following a needlestick injury, despite early prophylactic treatment with zidovudine. Worldwide cases recorded of occupational transmission of HIV; The index case; Discussion.关键词:...
Our aim was to explore the potential of co-administering QUE and CUR NEs by nasal route as a therapeutic and/or prophylactic treatment for viral respiratory infections. In this case, as we would like to administer it topically to the nasal mucosa, we changed the lipids and surfactant ...
(i.e.,0.8% NaCl) and uninfected cells were used as negative controls for the treatment and for the infection, respectively. W/o, without. qPCR, quantitative PCR.BQuantification of mRNA abundance relative to that in vehicle control cells (2−ΔΔCt) of sgN, E and ORF1AB genes from ...
RNAseq analyses was then performed on the SARS-CoV-2-infected Caco-2 cells pre-treated with Solution-3 (0.01x) or with vehicle (0.8% NaCl) for 48 h (Additional file1: Figure S3C), thus identifying n.5353 DEGs (fold-change of 2, p-value < 0.05) upon treatment with the nutraceu...
this suggests that the most effective intervention and the fastest way for the United States to achieve the goal of CC elimination is to scale up screening and treatment, especially focusing on the under-screened and undertreated [27]. There is evidence from multiple countries to support a reduc...
Janssen R&D Ireland (Janssen) announced today it has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 (HIV-1) medicine rilpivirine in a long-acting injection (depot formulation) as pote...
Collectively, these findings suggest that EKL1C is a promising candidate for further development as a potent and stable pan-HCoV fusion inhibitor that can be used alone or in combination with other broad-spectrum anti-HCoV drugs for the treatment and prevention of infection by SARS-CoV-2 and ...
Vaccination is one of the most significant developments in modern science, improving the treatment and controlling the spread of diseases across communities. For formulation scientists and immunologists, there has been an interest in the development of liposomal vaccines for their prophylactic uses in inf...